Rui Zhang1, Rebecca M Howell1, Phillip J Taddei2, Annelise Giebeler3, Anita Mahajan4, Wayne D Newhauser5. 1. The University of Texas Graduate School of Biomedical Sciences at Houston, USA; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA. 2. The University of Texas Graduate School of Biomedical Sciences at Houston, USA; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Radiation Oncology, American University of Beirut Medical Center, Lebanon. 3. The University of Texas Graduate School of Biomedical Sciences at Houston, USA; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA; Current address is: Scripps Proton Therapy Center, San Diego, CA, USA. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 5. The University of Texas Graduate School of Biomedical Sciences at Houston, USA; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA; Medical Physics Program, Department of Physics and Astronomy, Louisiana State University, Baton Rouge, USA. Electronic address: newhauser@lsu.edu.
Abstract
PURPOSE: To compare the risks of radiogenic second cancers and cardiac mortality in 17 pediatric medulloblastoma patients treated with passively scattered proton or field-in-field photon craniospinal irradiation (CSI). MATERIAL/ METHODS: Standard of care photon or proton CSI treatment plans were created for all 17 patients in a commercial treatment planning system (TPS) (Eclipse version 8.9; Varian Medical Systems, Palo Alto, CA) and prescription dose was 23.4 or 23.4 Gy (RBE) to the age specific target volume at 1.8 Gy/fraction. The therapeutic doses from proton and photon CSI plans were estimated from TPS. Stray radiation doses were determined from Monte Carlo simulations for proton CSI and from measurements and TPS for photon CSI. The Biological Effects of Ionization Radiation VII report and a linear model based on childhood cancer survivor data were used for risk predictions of second cancer and cardiac mortality, respectively. RESULTS: The ratios of lifetime attributable risk (RLARs) (proton/photon) ranged from 0.10 to 0.22 for second cancer incidence and ranged from 0.20 to 0.53 for second cancer mortality, respectively. The ratio of relative risk (RRR) (proton/photon) of cardiac mortality ranged from 0.12 to 0.24. The RLARs of both cancer incidence and mortality decreased with patient's age at exposure (e), while the RRRs of cardiac mortality increased with e. Girls had a significantly higher RLAR of cancer mortality than boys. CONCLUSION: Passively scattered proton CSI provides superior predicted outcomes by conferring lower predicted risks of second cancer and cardiac mortality than field-in-field photon CSI for all medulloblastoma patients in a large clinically representative sample in the United States, but the magnitude of superiority depends strongly on the patients' anatomical development status.
PURPOSE: To compare the risks of radiogenic second cancers and cardiac mortality in 17 pediatric medulloblastomapatients treated with passively scattered proton or field-in-field photon craniospinal irradiation (CSI). MATERIAL/ METHODS: Standard of care photon or proton CSI treatment plans were created for all 17 patients in a commercial treatment planning system (TPS) (Eclipse version 8.9; Varian Medical Systems, Palo Alto, CA) and prescription dose was 23.4 or 23.4 Gy (RBE) to the age specific target volume at 1.8 Gy/fraction. The therapeutic doses from proton and photon CSI plans were estimated from TPS. Stray radiation doses were determined from Monte Carlo simulations for proton CSI and from measurements and TPS for photon CSI. The Biological Effects of Ionization Radiation VII report and a linear model based on childhood cancer survivor data were used for risk predictions of second cancer and cardiac mortality, respectively. RESULTS: The ratios of lifetime attributable risk (RLARs) (proton/photon) ranged from 0.10 to 0.22 for second cancer incidence and ranged from 0.20 to 0.53 for second cancer mortality, respectively. The ratio of relative risk (RRR) (proton/photon) of cardiac mortality ranged from 0.12 to 0.24. The RLARs of both cancer incidence and mortality decreased with patient's age at exposure (e), while the RRRs of cardiac mortality increased with e. Girls had a significantly higher RLAR of cancer mortality than boys. CONCLUSION: Passively scattered proton CSI provides superior predicted outcomes by conferring lower predicted risks of second cancer and cardiac mortality than field-in-field photon CSI for all medulloblastomapatients in a large clinically representative sample in the United States, but the magnitude of superiority depends strongly on the patients' anatomical development status.
Authors: Igor Shuryak; Philip Hahnfeldt; Lynn Hlatky; Rainer K Sachs; David J Brenner Journal: Radiat Environ Biophys Date: 2009-06-05 Impact factor: 1.925
Authors: Igor Shuryak; Philip Hahnfeldt; Lynn Hlatky; Rainer K Sachs; David J Brenner Journal: Radiat Environ Biophys Date: 2009-06-18 Impact factor: 1.925
Authors: Marie E Wood; Victor Vogel; Andrea Ng; Lewis Foxhall; Pamela Goodwin; Lois B Travis Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Daniel A Mulrooney; Mark W Yeazel; Toana Kawashima; Ann C Mertens; Pauline Mitby; Marilyn Stovall; Sarah S Donaldson; Daniel M Green; Charles A Sklar; Leslie L Robison; Wendy M Leisenring Journal: BMJ Date: 2009-12-08
Authors: Annelise Giebeler; Wayne D Newhauser; Richard A Amos; Anita Mahajan; Kenneth Homann; Rebecca M Howell Journal: Radiat Oncol Date: 2013-02-03 Impact factor: 3.481
Authors: James E Bates; Rebecca M Howell; Qi Liu; Yutaka Yasui; Daniel A Mulrooney; Sughosh Dhakal; Susan A Smith; Wendy M Leisenring; Daniel J Indelicato; Todd M Gibson; Gregory T Armstrong; Kevin C Oeffinger; Louis S Constine Journal: J Clin Oncol Date: 2019-03-12 Impact factor: 44.544
Authors: Jillian R Gunther; Ahmad R Rahman; Wenli Dong; Zeinab Abou Yehia; Partow Kebriaei; Gabriela Rondon; Chelsea C Pinnix; Sarah A Milgrom; Pamela K Allen; Bouthaina S Dabaja; Grace L Smith Journal: Pract Radiat Oncol Date: 2017-05-10